Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
South Korea flag South Korea · Delayed Price · Currency is KRW
11,400
+220 (1.97%)
At close: Apr 2, 2026

KRX:007570 Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
204,345233,921205,533281,258349,981510,655
Market Cap Growth
-22.01%13.81%-26.92%-19.64%-31.46%-57.37%
Enterprise Value
306,431341,842341,070394,941436,337605,360
Last Close Price
11400.0012895.0011274.4815257.9318681.4826877.80
PE Ratio
30.4033.8822.76-18.4936.39
Forward PE
-49.9049.9049.9049.9049.90
PS Ratio
0.750.860.771.061.412.11
PB Ratio
0.850.970.861.221.472.25
P/TBV Ratio
0.871.000.881.261.512.32
P/FCF Ratio
32.3236.99-32.19180.6213.07
P/OCF Ratio
16.9719.4336.6019.2459.499.93
EV/Sales Ratio
1.121.251.271.481.762.50
EV/EBITDA Ratio
24.5925.6917.5413.9316.7722.92
EV/EBIT Ratio
74.4068.8835.4524.1130.6239.86
EV/FCF Ratio
48.4654.06-45.21225.1915.50
Debt / Equity Ratio
0.530.530.450.320.310.43
Debt / EBITDA Ratio
9.539.535.542.562.853.73
Debt / FCF Ratio
20.0520.05-8.3238.242.52
Net Debt / Equity Ratio
0.400.400.400.260.260.24
Net Debt / EBITDA Ratio
7.307.304.882.082.362.08
Net Debt / FCF Ratio
15.3715.37-2.916.7531.751.41
Asset Turnover
0.610.610.650.670.600.56
Inventory Turnover
2.522.522.792.963.463.40
Quick Ratio
0.460.460.390.470.460.59
Current Ratio
0.860.860.800.890.820.81
Return on Equity (ROE)
2.97%2.97%3.95%-0.87%8.53%6.25%
Return on Assets (ROA)
0.70%0.70%1.46%2.57%2.17%2.21%
Return on Invested Capital (ROIC)
0.77%0.79%2.63%5.56%4.07%3.45%
Return on Capital Employed (ROCE)
1.70%1.70%3.50%6.50%5.50%6.00%
Earnings Yield
3.38%2.95%4.39%-0.86%5.54%2.75%
FCF Yield
3.09%2.70%-15.85%3.11%0.55%7.65%
Dividend Yield
1.34%--0.98%--
Payout Ratio
41.72%41.72%32.93%-20.34%16.74%
Buyback Yield / Dilution
0.11%0.11%-2.29%0.59%0.44%-
Total Shareholder Return
1.44%0.11%-2.29%1.57%0.44%-
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.